Noshin Noorjahan

[Nature Reviews Urology] Preclinical prostate cancer models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumor xenograft models, patient-derived xenograft and circulating tumour cell eXplant models, as well as transgenic and knockout mouse models.

[Cipla] Cipla announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the US FDA based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.

[Monash University] Congratulations to Dr Pierre-Antoine Dugué awarded the Victorian Cancer Agency Mid-Career Research Fellowship worth $681,808. The fellowships are part of an $8.5 million plan to fund new ways to detect and treat a host of cancers.

[Nature Communications] Investigators reported that Large Tumor Suppressor 1 (LATS1), whose expression is often downregulated in human breast cancer, helped maintain luminal breast cancer cell identity by reducing the chromatin accessibility of genes that were characteristic of a “basal-like” state, preventing their spurious activation.

[Nature Communications] Researchers revealed that selective hyper-activation of functional enhancer of zeste homolog 2 (EZH2) (H3K27me3) over non-catalytic EZH2 altered TNBC metastatic landscape and fostered its peritoneal metastasis, particularly splenic.

[EMBO Molecular Medicine] By performing a high-throughput luciferase screening of 54 candidate miRNAs, the authors identified miR-182-3p as a specific and efficient post-transcriptional regulator of telomeric repeat-binding factor 2 (TRF2).